JP6598262B2 - 神経発生性疾患および障害を処置する方法 - Google Patents

神経発生性疾患および障害を処置する方法 Download PDF

Info

Publication number
JP6598262B2
JP6598262B2 JP2017516008A JP2017516008A JP6598262B2 JP 6598262 B2 JP6598262 B2 JP 6598262B2 JP 2017516008 A JP2017516008 A JP 2017516008A JP 2017516008 A JP2017516008 A JP 2017516008A JP 6598262 B2 JP6598262 B2 JP 6598262B2
Authority
JP
Japan
Prior art keywords
hda
disorders
asd
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017516008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517574A5 (enExample
JP2017517574A (ja
Inventor
チャン，スティーブ
チン ブーン，ワー
Original Assignee
ディーキン・ユニバーシティー
ザ フローリー インスティテュート オブ ニューロサイエンス アンド メンタル ヘルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902173A external-priority patent/AU2014902173A0/en
Application filed by ディーキン・ユニバーシティー, ザ フローリー インスティテュート オブ ニューロサイエンス アンド メンタル ヘルス filed Critical ディーキン・ユニバーシティー
Publication of JP2017517574A publication Critical patent/JP2017517574A/ja
Publication of JP2017517574A5 publication Critical patent/JP2017517574A5/ja
Application granted granted Critical
Publication of JP6598262B2 publication Critical patent/JP6598262B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017516008A 2014-06-06 2015-06-05 神経発生性疾患および障害を処置する方法 Active JP6598262B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014902173 2014-06-06
AU2014902173A AU2014902173A0 (en) 2014-06-06 Methods of treating neurodevelopmental diseases and disorders
PCT/AU2015/050310 WO2015184509A1 (en) 2014-06-06 2015-06-05 Methods of treating neurodevelopmental diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019174687A Division JP6994613B2 (ja) 2014-06-06 2019-09-25 神経発生性疾患および障害を処置する方法

Publications (3)

Publication Number Publication Date
JP2017517574A JP2017517574A (ja) 2017-06-29
JP2017517574A5 JP2017517574A5 (enExample) 2018-06-14
JP6598262B2 true JP6598262B2 (ja) 2019-10-30

Family

ID=54765877

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017516008A Active JP6598262B2 (ja) 2014-06-06 2015-06-05 神経発生性疾患および障害を処置する方法
JP2019174687A Active JP6994613B2 (ja) 2014-06-06 2019-09-25 神経発生性疾患および障害を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019174687A Active JP6994613B2 (ja) 2014-06-06 2019-09-25 神経発生性疾患および障害を処置する方法

Country Status (12)

Country Link
US (3) US9925163B2 (enExample)
EP (1) EP3151824B1 (enExample)
JP (2) JP6598262B2 (enExample)
KR (1) KR102496390B1 (enExample)
CN (1) CN106659704B (enExample)
AU (3) AU2015271652B2 (enExample)
BR (1) BR112016028653A2 (enExample)
CA (1) CA2951288C (enExample)
ES (1) ES3014042T3 (enExample)
MX (1) MX377588B (enExample)
NZ (1) NZ727412A (enExample)
WO (1) WO2015184509A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016028653A2 (pt) 2014-06-06 2018-07-10 Deakin University métodos de tratamento de doenças e distúrbios neurodesenvolvimentais
AU2016364670B2 (en) * 2015-12-04 2022-08-04 Wah Chin Boon Methods of treating or alleviating mental disorders and associated symptoms
CN116570582A (zh) * 2023-05-19 2023-08-11 中国药科大学 10-羟基癸烯酸在制备重度抑郁治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1025185A (en) 1911-03-23 1912-05-07 William J Gruss Regrinder.
JPH0967252A (ja) 1995-09-05 1997-03-11 Zenkoku Royal Jelly Kosei Torihiki Kiyougikai ローヤルゼリーに含まれるトランス−１０−ヒドロキシ−デセン酸を有効成分とするアンジオテンシン転換酵素阻害剤及びインスリン様作用剤
WO2007130581A2 (en) 2006-05-04 2007-11-15 Hardwicke Susan B Compositions and methods for psychiatric conditions and cognition enhancement
WO2009038110A1 (ja) 2007-09-19 2009-03-26 Nagoya Industrial Science Research Institute 神経栄養因子様作用剤
WO2009154197A1 (ja) 2008-06-17 2009-12-23 ジャパンローヤルゼリー株式会社 認知障害改善剤
LT2667715T (lt) * 2011-01-27 2017-11-10 Neuren Pharmaceuticals Limited Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį
US10052319B2 (en) * 2012-04-26 2018-08-21 Sumitomo Dainippon Pharma Co., Ltd. Medicament for treating mental and behavioural disorders
RU2602810C2 (ru) * 2012-04-27 2016-11-20 Ниппон Дзоки Фармасьютикал Ко., Лтд. Производное транс-2-деценовой кислоты и содержащее его лекарственное средство
CN103816307B (zh) 2014-03-12 2016-09-14 张国显 神经生长再造丸及其制备方法
BR112016028653A2 (pt) 2014-06-06 2018-07-10 Deakin University métodos de tratamento de doenças e distúrbios neurodesenvolvimentais
AU2016364670B2 (en) 2015-12-04 2022-08-04 Wah Chin Boon Methods of treating or alleviating mental disorders and associated symptoms

Also Published As

Publication number Publication date
US10933043B2 (en) 2021-03-02
AU2021221914A1 (en) 2021-09-23
US20180214405A1 (en) 2018-08-02
EP3151824A1 (en) 2017-04-12
ES3014042T3 (en) 2025-04-16
US10251856B2 (en) 2019-04-09
MX377588B (es) 2025-03-10
JP2019214623A (ja) 2019-12-19
CA2951288A1 (en) 2015-12-10
BR112016028653A2 (pt) 2018-07-10
KR20170026457A (ko) 2017-03-08
CA2951288C (en) 2024-01-02
US20190314315A1 (en) 2019-10-17
NZ727412A (en) 2023-07-28
CN106659704A (zh) 2017-05-10
AU2015271652A1 (en) 2017-01-05
CN106659704B (zh) 2020-03-10
US9925163B2 (en) 2018-03-27
JP6994613B2 (ja) 2022-01-14
MX2016016118A (es) 2017-07-26
WO2015184509A1 (en) 2015-12-10
KR102496390B1 (ko) 2023-02-03
JP2017517574A (ja) 2017-06-29
US20170087110A1 (en) 2017-03-30
AU2015271652B2 (en) 2021-05-27
EP3151824A4 (en) 2017-12-20
AU2025200041A1 (en) 2025-01-23
EP3151824B1 (en) 2025-03-05
EP3151824C0 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
AU2025200041A1 (en) Methods of treating neurodevelopmental diseases and disorders
TW201605443A (zh) 治療ｘ染色體脆折症及相關病症的方法
US20220117925A1 (en) Methods of treating or alleviating mental disorders and associated symptoms
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
KR20070084123A (ko) 양극성 장애 및 관련 증상의 치료
CA3129749A1 (en) Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
US20240398855A1 (en) Bromide source for use in treating autism spectral disorder
HK1232805A1 (en) Methods of treating neurodevelopmental diseases and disorders
CN105497021A (zh) 胺类化合物治疗焦虑障碍的医药用途
WO2023215338A1 (en) Compositions and methods for treating cluster headache
CN105456257A (zh) 胺类化合物的光学异构体治疗焦虑障碍的医药用途
CN111225667A (zh) 一种1,2,3,6,7-五甲氧基二苯吡酮在制备防治海马神经元相关疾病药物的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170505

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190926

R150 Certificate of patent or registration of utility model

Ref document number: 6598262

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250